The subsidiary is the Taiwan-based firm's first and potentially could provide it access to the genetic testing markets in Laos, Cambodia, Vietnam, and Indonesia.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The Australian company incorporated the subsidiary as it plans for the US launch of its ResistancePlus MG assay.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
Sweden-based Immunovia is preparing to launch its first diagnostic — a liquid biopsy test for pancreatic cancer — in 2018.
The subsidiary is being formed in support of Biocartis' recent US distribution deal with Thermo Fisher Scientific.
Jason Terrell will lead the subsidiary, which will be based in Austin, Texas.